Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-Current Deffered Revenue (2016 - 2025)

CytomX Therapeutics' Non-Current Deffered Revenue history spans 12 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 94.08% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, down 94.08%, while the annual FY2025 figure was $1.6 million, 94.08% down from the prior year.
  • Non-Current Deffered Revenue reached $1.6 million in Q4 2025 per CTMX's latest filing, down from $5.5 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $267.8 million in Q1 2021 to a low of $1.6 million in Q4 2025.
  • Average Non-Current Deffered Revenue over 5 years is $124.3 million, with a median of $126.6 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: rose 25.52% in 2021, then tumbled 94.08% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $243.9 million in 2021, then fell by 26.19% to $180.1 million in 2022, then crashed by 55.54% to $80.0 million in 2023, then crashed by 66.44% to $26.9 million in 2024, then crashed by 94.08% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Non-Current Deffered Revenue are $1.6 million (Q4 2025), $5.5 million (Q3 2025), and $10.2 million (Q2 2025).